NASDAQ:RGNX - Regenxbio Stock Price, Forecast & News

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio Inc (NASDAQ:RGNX) announced its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.03. The biotechnology company had revenue of $14.70 million for the quarter, compared to analysts' expectations of $7.46 million. Regenxbio had a negative net margin of 99.57% and a negative return on equity of 18.74%. The firm's quarterly revenue was up 177.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.56) earnings per share. View Regenxbio's Earnings History.

Regenxbio is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Regenxbio.

6 Wall Street analysts have issued 12 month price objectives for Regenxbio's stock. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's share price to reach $80.80 in the next year. This suggests a possible upside of 79.0% from the stock's current price. View Analyst Price Targets for Regenxbio.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.

News headlines about RGNX stock have trended somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regenxbio earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Regenxbio.

Some companies that are related to Regenxbio include argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD) and Denali Therapeutics (DNLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Visa (V), Amarin (AMRN), Exelixis (EXEL), Square (SQ), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Alibaba Group (BABA) and Intercept Pharmaceuticals (ICPT).

Regenxbio's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.20%), State of Alaska Department of Revenue (0.06%), Prentiss Smith & Co. Inc. (0.03%), Louisiana State Employees Retirement System (0.03%), Sanders Morris Harris LLC (0.02%) and NEXT Financial Group Inc (0.01%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, State of Alaska Department of Revenue and NEXT Financial Group Inc. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas and Vittal Vasista. View Insider Buying and Selling for Regenxbio.

RGNX stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Sanders Morris Harris LLC, Prentiss Smith & Co. Inc. and IFP Advisors Inc. View Insider Buying and Selling for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $45.14.

Regenxbio has a market capitalization of $1.66 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.

The official website for Regenxbio is http://www.regenxbio.com/.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]